Profound Medical (PROF) Set to Post Earnings on Thursday

Profound Medical (NASDAQ:PROF) is projected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Profound Medical to announce earnings of ($0.1920) per share and revenue of $8.82 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Profound Medical had a negative return on equity of 63.03% and a negative net margin of 171.57%. The business had revenue of $2.48 million during the quarter, compared to analysts’ expectations of $4.75 million. On average, analysts expect Profound Medical to post ($0.79) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

Profound Medical Stock Performance

Shares of PROF stock opened at $6.99 on Wednesday. The stock has a 50 day moving average price of $6.23 and a 200 day moving average price of $6.67. Profound Medical has a 52-week low of $4.80 and a 52-week high of $8.95. The firm has a market capitalization of $255.55 million, a P/E ratio of -7.13 and a beta of 0.79.

Analyst Ratings Changes

A number of analysts have recently issued reports on PROF shares. Weiss Ratings lowered shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Wall Street Zen raised Profound Medical from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, Raymond James Financial raised shares of Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price target on the stock in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Profound Medical currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Profound Medical Company Profile

Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company’s flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time.

TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.